1. Nat. Rev. Cardiol. doi:10.1038/nrcardio.2016.96
Figure 2 An analysis of potentialin crement a l costof shifting from using
intra-aortic balloon pumps (IABP) to percutaneous left ventricular assist devices (pVAD)
Figure 2 | An analysis of potential incremental cost of shifting from using intra-aortic balloon pumps (IABP) to percutaneous left ventricular assist devices (pVAD). The data show an incremental increase in cost of $33,957,839 for the hospital system in the USA associated with use of pVAD in patients with cardiogenic shock undergoing percutaneous coronary intervention, without an associated improvement in mortality, reduced hospital length of stay, or hospital readmission. Reprinted from Shah, A. et al. Clinical and economic effectiveness of percutaneous ventricular assist devices for high-risk patients undergoing percutaneous coronary intervention. J. Invasive Cardiol. 27, 148–154 (2015), with permission from HMP Communications.
Reprinted from Shah, A. et al. Clinical and economic effectiveness of percutaneous ventricular assist devices for high-risk patients
undergoing percutaneous coronary intervention. J. Invasive Cardiol. 27, 148–154 (2015), with permission from HMP Communications
Reyentovich, A. et al. (2016) Management of refractory cardiogenic shock
Nat. Rev. Cardiol. doi: /nrcardio